GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Ending Cash Position

CTLT (Catalent) Ending Cash Position : $335 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Ending Cash Position?

Catalent's Ending Cash Position for the quarter that ended in Sep. 2024 was $335 Mil.

Catalent's quarterly Ending Cash Position increased from Mar. 2024 ($162 Mil) to Jun. 2024 ($289 Mil) and increased from Jun. 2024 ($289 Mil) to Sep. 2024 ($335 Mil).

Catalent's annual Ending Cash Position declined from Jun. 2022 ($449 Mil) to Jun. 2023 ($280 Mil) but then increased from Jun. 2023 ($280 Mil) to Jun. 2024 ($289 Mil).

Catalent Ending Cash Position Historical Data

The historical data trend for Catalent's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Ending Cash Position Chart

Catalent Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 953.00 896.00 449.00 280.00 289.00

Catalent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.00 229.00 162.00 289.00 335.00

Catalent Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Catalent's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=280+9
=289

Catalent's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=289+46
=335

Catalent Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Catalent's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Ending Cash Position
Comparable Companies
ITCI NBIX VTRS LNTH ELAN ALKS PBH ALVO PRGO AMRX ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ SZSE:000538
Traded in Other Exchanges
N/A
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Website
https://www.catalent.com
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
Joseph Anthony Ferraro officer: SVP, General Counsel, CCO 56 EMILY ROAD, FAR HILLS FL 07931
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lisa Evoli officer: SVP, Chief HR Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Matti Masanovich officer: SVP, Chief Financial Officer COLLINS & AIKMAN CORPORATION, 250 STEPHENSON HIGHWAY, TROY MI 48083
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Jonathan Arnold officer: President, Oral Drug Delivery C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven L Fasman officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873